Manufacturers of biopharmaceuticals can improve productivity by taking patient wellness into account.
Productivities similar to those achieved with stirred tanks can be achieved with disposable bioreactors.
Best methods to maximize product yield and membrane lifetime to enhance a tangential flow filtration process.
Productivities similar to those achieved with stirred tanks can be achieved with disposable bioreactors.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Contract manufacturers must plan for increased analytical resources in development and quality control.
An off-the-shelf, single-use perfusion system.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
Webinar Date/Time: Tue, Jun 3, 2025 2:00 PM EDT
A twin-column periodic countercurrent capture process that combines an efficient sequential, countercurrent loading process with a minimal twin-column hardware configuration is described.
A simple method to leverage fermentation heat transfer data.
Experimenting with a rival?s patented compound may land you in hot water.
Can increase in ionic strength result in higher viscosity?
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
Can increase in ionic strength result in higher viscosity?
NeisVac-C is a polysaccharide-protein conjugate vaccine for use against Neisseria meningitidis serogroup C infection. The Phase 1 clinical formulation consisted of physiological saline, thimerosal, and aluminum hydroxide. The long-term stability data for both the PBS and saline formulations are presented in this article.
A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
A review of some recent contributions in process chromatography.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
Manufacturing challenges surround the use of IgM monoclonal antibodies, but these can be overcome with current technology.
Single-use systems have greatly improved and simplified common manufacturing issues.
Several legal considerations are key to protect the buyer and seller in royalty interest transactions.
Avoid manufacturing failures by effective viral inactivation.
As more biotechs turn to convertible note financing instead of traditional venture capital, they need to be aware of investors' demands.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.